Anavex Life Sciences COO Departs Amid Leadership Reorganization

summarizeSummary

Anavex Life Sciences announced the departure of its Chief Operating Officer, Felix Lauscher, on May 11, 2026, as part of a broader reorganization following recent CEO changes.

check_boxKey Events

• Chief Operating Officer Departs

  Felix Lauscher, who served as Chief Operating Officer since March 1, 2026, departed from the company on May 11, 2026.

• Part of Broader Reorganization

  The departure is explicitly stated as part of a broader reorganization of duties following the recent appointment of Dr. Terrie Kellmeyer as Interim Chief Executive Officer.

• Short Tenure

  Mr. Lauscher's tenure as COO was brief, lasting just over two months, indicating rapid executive turnover.

auto_awesomeAnalysis

This filing confirms further executive instability at Anavex Life Sciences, with the Chief Operating Officer departing just days after the previous CEO was terminated for cause and an interim CEO was appointed. The short tenure of the departing COO (just over two months) highlights the rapid and significant leadership changes underway, which could impact operational continuity and strategic direction.